


# ***Herpesviruses: Latent and Lytic Infection***




***Viruses, Cells and Disease  
November 6, 2008***

# Diversity within DNA viruses


<u>Classification</u>	<u>Example</u>	<u>Genome size</u>	<u># genes</u>	<u>envelope?</u>	<u>Unique features</u>
<u>Polyomavirus</u>	SV40	5 kb. ds	7	NO	Transformation
<u>Papillomavirus</u>	HPV	8 kb. ds	10	NO	>100 strains; Cervical cancer agent; Transformation following integration
<u>Adenovirus</u>	Ad2, Ad5	36 kb.ds	14 tx. Units	NO	Leader RNAs; Common respiratory pathogen; Transformation; Gene therapy vector
<u>Parvovirus</u>	AAV	5 kb. ss	2	NO	Require helper virus; Gene therapy vector
<u>Herpesvirus</u>	HSV (HHV-1)	152 kb. ds	86	YES	Tegument
	HCMV (HHV-5)	235 kb. ds	222		Latency
	EBV (HHV-4)	172 kb. ds	82		Transformation
	KSHV (HHV-8)	170 kb. ds	86		Neural gene therapy vector
<u>Poxvirus</u>	Vaccinia	200 kb. ds	150	YES	Smallpox agent (Variola); Cytoplasmic replication (RNA pol, capping enz, poly(A) pol)
<u>Hepadnavirus</u>	HBV	3.2 kb ds*	8	YES	RNA repli. Intermediate; Hepatitis agent; liver cancer; 1st recomb. vaccine

# Herpesviruses




- **Extremely common, highly disseminated in nature**
- **>200 herpesviruses identified to date**
- **Every mammal is infected by at least one:  
Eight have been isolated from humans**
- **Spread through direct physical contact**
- **Alternating Lytic (Productive) infection and  
Latent (non-productive) infection**

# Virion Structure



icosahedral  
nucleocapsid  
dsDNA genome  
envelope  
tegument  
glycoprotein



**Human Herpesviruses genomes:**  
**150-235 kb. DNA, encode 80-225 proteins**

**Tegument: >20 proteins**

## **Classification:** Three subfamilies -

### **$\alpha$ herpesviruses:**

Human herpesvirus 1,2 **Herpes simplex virus 1, 2 (HSV-1, HSV-2)**

Human herpesvirus 3 **Varicella-Zoster virus (VZV)**

- a relatively rapid, cytocidal growth cycle
- establish latent infections primarily in sensory ganglia

### **$\beta$ herpesviruses:**

Human herpesvirus 5 **Cytomegalovirus (CMV)**

Human herpesvirus 6 **HHV-6**

Human herpesvirus 7 **HHV-7**

- the reproductive cycle is long and grow slowly in culture
- establish latency in monocytes (CMV) or T cells (HHV-6, 7)


### **$\gamma$ herpesviruses:**

Human herpesvirus 4 **Epstein Barr virus (EBV)**

Human herpesvirus 8 **Kaposi's sarcoma associated herpesvirus (KSHV/HHV-8)**

- establish latency in B cells
- can transform cells; they are oncogenic herpesviruses

# Although divergent in size and genomic architecture, herpesviruses share 7 conserved blocks of ancient genes



# Approximately 40 core genes are conserved among all herpesviruses

## Gene regulation

Transcriptional/post-transcriptional  
transactivator

## Nucleotide Metabolism

Ribonucleotide reductase, large subunit  
Uracil DNA glycosylase  
dUTPase

## DNA Replication

Helicase/primase (3 subunits)  
DNA polymerase\*\*  
Polymerase processivity factor  
ssDNA binding

## Other

Cell-to-cell fusion

## Virion

### Maturation

Alkaline exonuclease	Transport
Terminase/packaging	Scaffold protease
Capsid nuclear egress (2)	Virion protein
Genome cleavage/packaging (3)	Scaffold

### Capsid

Major capsid protein (MCP)
Minor capsid protein      Hexon tips
Capsid triplex (2)



### Tegument

Large tegument protein	Protein kinase
6 with unknown function	


### Envelope

Glycoproteins B (gB), gH, gL, gM, gN


**Patterns of herpesviral replication**  
**must be considered at the cellular and organismal levels**



# Reproduction and transmission determine the biological success of a virus



# Viral genes are expressed in a cascade fashion during replication of a DNA virus



# **Productive gene expression cascade of herpesviruses**

## **Immediate Early (IE; $\alpha$ ) genes:**

**CHX resistant (no prior protein synthesis req).**

**Transcriptional and post-transcriptional activation and de-repression.      Inhibit IFN response**

**Pro and anti-apoptotic      Block antigen presentation**

**Reduce host gene expression      E3 ubiquitin ligase**

## **Delayed Early (DE; $\beta$ ) genes:** all require prior expression of combinations of IE transactivators


**Do not require prior viral DNA replication**

**Can function as DE genes when present on a plasmid**


## **Late (L; $\gamma$ ) genes:** expression enhanced by viral DNA synthesis require IE transactivators + ssDNA binding protein (DE) **$\gamma$ 1-expression does not require viral DNA synthesis** **$\gamma$ 2-expression strictly dependent on viral DNA synthesis** **Not understood--cis acting regulation**

# Small DNA viruses, but not herpesviruses, target central growth control proteins to replicate productively

## Small DNA Viruses (Papova and Adenoviruses)



## Herpesviruses



# Nuclear events--the goal is to replicate viral DNA

Viral coding capacity generally predicts autonomy vs. reliance on host functions

Function	SV40	HSV-1
DNA pol	<i>cellular DNA pol <math>\delta</math></i>	UL30
Pol processivity	<i>cellular PCNA</i>	UL42
ssDNA binding protein	<i>cellular RF-A</i>	UL29
helicase/primase	<b>Large T antigen</b>	UL5,8,52
Origin binding protein	<b>Large T antigen</b>	UL9
RNAse H/5'-3' exonuclease	<i>cellular RNAse H, MF-1</i>	UL30,42
Nucleoside phosphotransferase	<i>cellular thymidine kinase</i>	UL23
Ribonucleotide reductase	<i>cellular</i>	UL39,40
Deoxyuridine triphosphatase	<i>cellular</i>	UL50
Deoxyribonuclease	<i>cellular</i>	UL12
Uracil-DNA-glycosylase	<i>cellular</i>	UL2
Topoisomerase I, II	<i>cellular</i>	<i>cellular</i>
RF-C	<i>cellular</i>	<i>cellular</i>
Ligase I	<i>cellular</i>	<i>cellular</i>

# **Lytic cycle (productive) herpesviral DNA replication**

**Requires: Lytic origin of replication (“ori<sub>Lyt</sub>”)**

**+**

**7 viral proteins that participate  
directly at replication fork.**


**Rolling circle replication**

**Cleavage of genome concatemers into single units**

**Produces linear genomes that are packaged into  
capsids**

# DE gene products replicate viral DNA

Challberg, 1986. PNAS, 83: 9094-8.



1) Co-transfect mammalian cells with plasmids encoding 7 viral proteins:

DNA polymerase

Polymerase processivity protein

ssDNA binding protein

Origin binding protein

3 helicase/primase proteins


2) Harvest viral DNA

3) Digest with Dpn I (digests transfected DNA ONLY)


+ specific REs

4) Southern blot for plasmid


# Successful replication leads to viral budding and cell lysis




# Herpesviruses establish latent, non-productive infections




In herpesviral reactivation, the gene expression cascade is probably identical as in primary, productive infection



# Experimental Models for Latency and Reactivation of Human herpesviruses are few in number.



Cellular level




Organismal level

Gamma-herpesviruses :Model: Herpes Simplex 1 and 2


Non-human herpesviruses provide animal models for others

# Herpesvirus Latency--Characteristics (cellular level)

1. Viral genomes persist as nuclear episomes:  
some herpesviruses express protein that tethers viral chromatin to host chromatin.
2. Viral DNA is nucleosomal.
3. Viral gene expression is extremely limited.
4. Viral DNA replicates along with host.  
Requires  $ori_{lat}$  + cellular replication machinery. Proceeds via a theta form.  
Yields circular progeny genomes.
5. Immune detection of the virus is reduced or eliminated.
6. Mature virions are not produced.
7. Establishment and maintenance of latency can  
quantitated separately. Establishment is not well-understood  
in herpesviruses.
8. Virus can be reactivated into productive cycle at a later time.



**Herpesviral infection alternates between  
productive and non-productive replication for the life of the host  
(organismal level)**



**Acute infection**

- Rhinovirus
- Rotavirus
- Influenza virus

**Persistent infection**

- Lymphocytic  
Choriomeningitis virus

**Latent, reactivating infection**

- Herpesviruses

# **Mechanisms that control productive vs. latent infection**

## **Lack of expression of immediate early (IE) genes.**

Expression is repressed by host cell factors  
(transcription factors or repressive chromatin).

Expression is repressed by viral factors

Absence of host cell factors

Lack of expression

Lack of proper modifications

Absence from nucleus

## **Inhibition of viral replication by the host immune response.**

## **Evidence supports a combination of all of the above.**

Balance between above mechanisms and those promoting productive infection  
probably determines outcome.

Specific players differ for different herpesviruses.

# Latent and Lytic Herpesviral replication is Cell and Disease-specific


<b>Classif.</b>	<b>Common name</b>	<b>LatentSite-Disease</b>	<b>Reactivation-Disease</b>
HHV-1	Herpes Simplex Virus-1	<u>Neurons</u> -none	<u>Cutaneous Epithelium</u> lesions-Face or Genital
HHV-2	Herpes Simplex Virus-2		
HHV-3	Varicella/Zoster Virus	<u>Neurons</u> -none	<u>Cutaneous Epithelium</u> lesions-shingles, pain
HHV-4	NEXT SLIDE		
HHV-5	Human cytomegalovirus	<u>Monocytes/</u> <u>Macrophages</u> -none	<u>Widespread Epithelium,</u> <u>and Endothelium</u> -Fever, Retinitis, Cardiovascular disease
HHV-6A HHV-6B		<u>Monocytes/Macro-</u> none <u>CD4+ T cells</u> -none	<u>Same-Bone Marrow</u> <u>Suppression, URI,</u> <u>AIDS dementia?</u>
HHV-7		<u>CD4+ T cells</u> -none	<u>Salivary Epithelium</u>
HHV-8	NEXT SLIDE		

**Only Epstein-Barr Virus (EBV)  
and Kaposi's sarcoma-associated Herpesvirus (KSHV)  
are conclusively associated with Human cancers.**


<b>Classif.</b>	<b>Common name</b>	<b>LatentSite-Disease</b>	<b>Reactivation-Disease</b>
<b>HHV-4</b>	<b>Epstein-Barr Virus</b>	<u>Resting, memory</u> <u>B cells-Lymphomas</u> , incl. Burkitt's, AIDS-associated, Hodgkin's disease, others <u>Nasal epithelium-</u> <u>Nasopharyngeal</u> <u>carcinoma</u>	<u>Oral epithelium-Oral</u> <u>Hairy Leukoplakia</u>
<b>HHV-8</b>	<b>Kaposi's sarcoma- associated Herpesvirus</b>	<u>B cells- Primary</u> <u>Effusion</u> <u>Lymphoma</u>	<u>Lymphatic</u> <u>Endothelium -</u> <u>Kaposi's sarcoma</u> <u>B cells-Multi-Centric</u> <u>Castleman's Disease</u>

# HSV Lifesycles


## A. Establishment of latent infection




## B. Reactivation of latent virus




# The trigeminal nerve is the major site of HSV-1 latency in mice and humans




# Comparative seroprevalence of HSV-1 and 2 in the US



# HSV virion protein (VP)-16: a paradigm for promoter-specific transactivation in viral replication




# Histone modifications are critical in the latent to lytic switch of HSV



Virus Res. 111: 108-119.

# Establishment/maintenance of HSV latency




**Productive infection**

**Latent infection**


Nat. Rev. Microbiol. 6: 211-221.

# Varicella-Zoster Viruses (VZV)

VZV gives rise to two distinct clinical syndromes



Varicella = Chicken pox  
Primary infection



Latency in  
ganglia




Zoster = Shingles  
Reactivation

# Chicken pox



# VZV Disease Mechanism



# Zoster (Shingles)


- ~ 1 million cases/year in US
- > 65 year old individuals
- Reactivation of VZV from dorsal root ganglia - viruses transport to skin
- Occurs only in persons who have previously had chicken pox
- Symptoms:  
A rash that develops into clear blisters (full of infectious virus) and moderate to severe pain, potentially dangerous in the elderly



# Epstein-Barr Virus (EBV)


- 1958- first described in a childhood tumor by Dr. Burkitt  
Burkitt's lymphoma  
1964- identified by Epstein and Barr by EM
- 90-95% of adults show evidence of EBV infection

## Primary Infection



## Latency and Reactivation

Lymphomas (occasional)



# Maintenance of EBV latency and transformation of B cells requires the same proteins.

1. To maintain a latent infection, EBV must stimulate growth and survival of host B cell. This can lead to lymphoma

Three EBV proteins are essential for latency/transformation:


**EBNA-2 (EBV nuclear antigen-2)** - a transcriptional activator that orchestrates latent gene expression

**LMP-1 (latent membrane protein-1)** - can transform permanent cell lines and induce B-cell lymphomas in transgenic mice.

**EBNA-1** - required for replicating the latent episomal genome, tethers genome to host chromosome

2. c-myc is overexpressed by one of two mechanisms:
  - a. **EBNA2** directly transactivates it
  - b. C-myc is translocated adjacent to a strong cellular promoter.
3. NF-kB is constitutively activated by **LMP-1**--inhibits apoptosis.

**LMP1, the major EBV oncoprotein, mimics constitutively active CD40 receptor to activate growth, division, of infected B cells**



# Kaposi's Sarcoma-Associated Herpesvirus (KSHV or HHV-8)

- KS was first described by Moritz Kaposi in the 1870s
- KS is a cancer that develops in lymphatic endothelial cells
- KS is more common in AIDS patients
  - 91,000 persons with AIDS (1989), 15% have KS
  - >20,000X more common in person with AIDS
  - ~300X more common in other immunosuppressed groups
- A sexually transmitted factor other than HIV plays a role in KS
  - KS is 10X more common in homosexual or bisexual men
- 1994, using a PCR-based technique Chang and Moore identified two small DNA fragments present in AIDS-KS samples - homology to EBV
- 4 clinico-epidemiologic forms: KSHV is etiologic agent of all.


## Kaposi's sarcoma in patients infected with HIV-1



Red, blue or purple flat or raised lesions.

# Primary Effusion Lymphoma cells: *The tissue culture system to study lytic reactivation of KSHV*

PEL cell



**KSHV is the etiologic agent of  
Primary Effusion Lymphoma (PEL)  
B cell lymphoma--  
B cells are KSHV reservoir *in vivo***


## PEL Cell Lines

Explanted from PEL patients  
50 copies KSHV per cell genome


## Latency

Virus is latent in >95% of cells  
Highly restricted viral gene expression  
(ca. 6 genes expressed)  
Little spontaneous reactivation


# In PEL cells, KSHV is reactivated by chemicals or by ectopic expression of the KSHV ORF50/Rta protein




# TPA induces expression of Rta, leading to a cascade of viral gene expression






# Does Herpesviral reactivation follow a gene expression cascade similar to that of de novo lytic infection?



# Rta is an inefficient reactivator



# Mta is a commitment factor for reactivation




## Pathogenesis?:

- KSHV encodes many homologues of cellular growth-control proteins. Most are expressed after reactivation.

<b>vIL-6:</b>	cell growth
<b>vBCL2:</b>	anti-apoptosis
<b>vIRF:</b>	inhibition of IFN signaling
<b>vCYC:</b>	cell cycle control
<b>vGPCR:</b>	(IL-8 receptor homolog) cell growth
<b>vCCLs:</b>	(chemokines) immune modulation


# Sub-optimal progression of KSHV reactivation probably contributes to pathogenesis










## **The host immune response tempers herpesviral reactivation and pathogenesis.**

- In immunocompromised hosts (AIDS, transplant, some elderly) herpesvirus reactivation ↑, viral load ↑, and risk and severity of disease ↑.
- Can often be reversed by restoring immunity.

# Role of immune system--modeling gamma-herpesvirus infection in the mouse (MHV-68)



# Role of immune system--modeling gamma-herpesvirus infection in the mouse (MHV-68)

	$\Delta$ CD8+	IFN $\gamma$ -/-	$\Delta$ MHC II	Autologous Primed CD4+	$\Delta$ B cells
# of latently-infected cells					
Lytic/Latent Infection					
Lymphoma regression					
Reactivation efficiency					
Longer period of reactivation					

**Assignment for Next Week:**

**Oral presentation of two papers  
on KSHV infection in humans**